9,361 Johnson & Johnson $JNJ Shares Sold by DMKC Advisory Services LLC

DMKC Advisory Services LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 36.0% during the third quarter, Holdings Channel reports. The fund owned 16,650 shares of the company’s stock after selling 9,361 shares during the quarter. Johnson & Johnson makes up 1.1% of DMKC Advisory Services LLC’s holdings, making the stock its 23rd largest holding. DMKC Advisory Services LLC’s holdings in Johnson & Johnson were worth $4,408,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also made changes to their positions in the company. Wellington Management Group LLP grew its position in Johnson & Johnson by 12.5% during the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after purchasing an additional 2,513,321 shares in the last quarter. Deutsche Bank AG lifted its holdings in shares of Johnson & Johnson by 8.5% in the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock valued at $3,977,506,000 after purchasing an additional 1,225,676 shares in the last quarter. Amundi lifted its holdings in shares of Johnson & Johnson by 17.5% in the first quarter. Amundi now owns 13,406,820 shares of the company’s stock valued at $3,277,163,000 after purchasing an additional 2,001,139 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Johnson & Johnson by 1.9% in the first quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company’s stock valued at $1,924,323,000 after purchasing an additional 148,497 shares in the last quarter. Finally, Jupiter Topco LLC acquired a new stake in shares of Johnson & Johnson in the second quarter worth $1,967,399,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: In a first-in-human Phase 1 study, the investigational pasritamig–JNJ-9401 combination produced a PSA reduction of at least 50% in 11 of 15 patients with advanced prostate cancer; nearly half had reductions of at least 90%. J&J reported an encouraging safety profile and said the regimen is advancing toward Phase 3, though the small early-stage study carries substantial uncertainty. Article: Johnson & Johnson reports 73% PSA response rate
• Positive Sentiment: ICOTYDE (icotrokinra) met the primary endpoint in a Phase 3 trial in biologic-naive patients with psoriatic arthritis, supporting the potential of this once-daily oral treatment. Article: ICOTYDE meets primary endpoint in Phase 3 study
• Positive Sentiment: J&J also presented new nipocalimab data in Sjögren’s disease and reported positive results for autoimmune therapies at a medical meeting, adding to the pipeline’s potential, although the reports provide limited detail on commercial impact. Article: New Phase 2 nipocalimab study data
• Negative Sentiment: ETF investors were net sellers of J&J shares on Nov. 5, a modestly negative flow signal that predates the latest trial announcements. Article: ETFs are net sellers of Johnson & Johnson

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 15,000 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president directly owned 194,451 shares of the company’s stock, valued at $51,210,615.36. This represents a 7.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on JNJ. Sanford C. Bernstein set a $270.00 price target on Johnson & Johnson in a report on Thursday, October 15th. Guggenheim reissued a “buy” rating and issued a $287.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 7th. Scotiabank restated an “outperform” rating and set a $305.00 price objective on shares of Johnson & Johnson in a research report on Thursday, July 16th. Leerink Partners decreased their price objective on Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating for the company in a research report on Wednesday, October 14th. Finally, Bank of America reaffirmed a “neutral” rating and set a $278.00 target price on shares of Johnson & Johnson in a research note on Tuesday, September 29th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $275.92.

Johnson & Johnson Stock Up 2.0%

JNJ stock opened at $281.86 on Tuesday. Johnson & Johnson has a 12-month low of $185.12 and a 12-month high of $282.73. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The company has a market cap of $678.53 billion, a price-to-earnings ratio of 42.71, a PEG ratio of 2.73 and a beta of 0.22. The company has a 50 day moving average of $266.18 and a two-hundred day moving average of $248.62.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. During the same quarter last year, the business posted $2.80 EPS. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 81.21%.

About Johnson & Johnson

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.